雅培公司 (ABT.US) 2025年第四季度业绩电话会
文章语言：
简
繁
EN
Share
Minutes
原文
会议摘要
Abbott's leadership highlighted achievements, future strategies, and targeted double-digit earnings growth for 2026, focusing on core diagnostics, electrophysiology, and medical devices. Despite nutrition segment challenges, the company expressed confidence in its pipeline, strategic acquisitions, and ability to sustain growth, emphasizing investments in key segments and readiness for future opportunities.
会议速览
Abbott's Q4 2025 Earnings Call: Guidance, Risks, and Non-GAAP MeasuresThe dialogue introduces Abbott's Q4 2025 earnings call, highlighting potential risks, forward-looking statements, and the use of non-GAAP financial measures. It outlines the call's structure, emphasizing organic sales growth and the disclaimer on recording and rebroadcasting without permission.
Abbott's 2025 Recap & 2026 Outlook: Innovation, Execution, & Strategic GrowthReflects on Abbott's 2025 achievements in innovation, execution, and strategic moves, including regulatory approvals, market expansions, and acquisitions. Highlights challenges in nutrition sales and strategies for volume growth. Forecasts 2026 with 7% organic sales growth and adjusted earnings per share increase, driven by innovation, operational excellence, and strategic execution.
Investment Strategy Yields Growth in Medical Device SegmentsA strategic approach to investing in medical device sectors, particularly in high-growth and foundational areas, has led to significant returns. Notably, advancements in rhythm management and vascular technologies, including the success of products like the spacemaker and Closure products, have driven market share gains. With the anticipated approval of a coronary IVL device and strong international performance of rechargeable spinal cord stimulation devices, the company is poised for accelerated growth, achieving double-digit earnings per share growth despite challenges.
Q4 Financial Highlights and FY2026 Guidance: Organic Growth and Adjusted Earnings OutlookFourth quarter sales grew by 3.8% organically, excluding Covid testing, with adjusted earnings per share up 12%. Guidance for 2026 forecasts 10% earnings growth, with organic sales growth and a favorable exchange impact expected. Adjusted operating margin improved by 150 basis points.
Revenue Growth Guidance Adjustment Due to Nutrition Segment ChallengesThe discussion revolves around a revision in revenue growth guidance, attributed to challenges within the nutrition segment. The adjustment reflects a strategic response to market dynamics, including cost surges and consumer price sensitivity, impacting volume growth. The company is optimistic about future growth prospects and portfolio strength, despite current economic pressures.
Strategies for Accelerating Growth Amidst Challenges in Nutrition and DiagnosticsThe company is implementing price promotions and launching new products to boost volume growth in nutrition, reallocating resources within the existing R&D budget. Despite challenges, significant growth is expected across various franchises, with the pharma business poised to overcome last year's diagnostic headwinds and expand with the addition of Exact Sciences. The transition back to volume-driven growth is anticipated to be quicker than previous disruptions, setting a positive trajectory for the year.
Avid's EP Portfolio Growth Strategy and Competitive Advantage with RF and PFA ProductsAvid's EP business strategy, emphasizing RF and PFA products, has sustained double-digit growth. The portfolio's completeness, including diagnostic elements and an LEAD device, positions Avid ahead of competitors. The successful launch of Volt and the introduction of Flex Duo Tact to Flex Duo Tact highlight Avid's commitment to providing a toolbox approach for physicians, enhancing procedural flexibility and patient outcomes.
Risk-Adjusted Guidance and Growth Strategy for 2026The dialogue highlights the company's strategic outlook for 2026, emphasizing risk-adjusted guidance and a commitment to high single-digit top-line growth with double-digit bottom-line gains. It discusses the careful consideration of various variables and the philosophy behind setting the guidance, reflecting the company's investment identity and strategic priorities.
Sustaining High Single-Digit Growth and Navigating Challenges in Key Business SegmentsThe dialogue outlines strategies for maintaining high single-digit growth in core business areas, including cardiovascular and diabetes products, while addressing challenges in diagnostics and nutrition segments. It highlights the impact of COVID-19 on sales and the potential for growth acceleration in diagnostics as market conditions improve. The speaker expresses confidence in reigniting volume growth in the nutrition sector and emphasizes the importance of strategic investments and margin expansion to support overall business momentum.
CGM Market Growth and Abbott's Strategic Positioning for Future ExpansionDiscussion highlights CGM market's potential for growth, emphasizing Abbott's strategic plans to increase market penetration and share, particularly through innovative products and international expansion. The dialogue addresses opportunities in non-insulin user segments, international markets, and the launch of differentiated products, showcasing readiness for future challenges and growth prospects.
Expanding Market Opportunities for Continuous Glucose Monitoring in Diabetes CareThe dialogue highlights the significant market potential for continuous glucose monitoring (CGM) devices, especially among SL T 2 users with low CGM penetration. It underscores the ongoing need for innovation and investment in diabetes care, emphasizing the robust growth and untapped opportunities in various patient segments and geographies.
Strategies for Sustained Margin Expansion and EPS Growth in 2026The dialogue focuses on achieving double-digit EPS growth in 2026 through top-line growth and margin expansion. The company commits to annual basis point improvements in operating margins, leveraging both gross margin expansion and strategic P&L leverage, ensuring continued excellence and execution despite uncertainties and volatilities.
Sustained Double-Digit Growth in Rhythm Management and Strategic Capital AllocationThe company is experiencing robust growth in the rhythm management segment, significantly outpacing the market's low single-digit growth. With a current penetration rate of around 10% in the global low-voltage pacing market, there is substantial room for expansion. The strategy involves continuous investment in product innovation and physician training, aiming to set a new standard of care. Additionally, discussions on capital allocation highlight the company's proactive approach to managing resources for future growth, emphasizing the launch of new products and supporting clinical evidence that validates the efficacy of their devices.
Strategic Capital Allocation, M&A Integration, and Pricing Confidence in Nutrition BusinessThe dialogue covers strategic capital allocation focusing on integration of Exact Sciences and potential tuck-in acquisitions, confidence in current nutrition pricing strategies based on market testing, and an evolving profitability profile within Abbott's portfolio. Emphasis is placed on maintaining a balanced short-term and long-term shareholder value creation approach.
Outlook for Diagnostics Growth Amidst China's Challenges and Potential Expansion in Non-Insulin Diabetes CoverageDiscusses the stability and growth prospects of the diagnostics business, highlighting efforts in China and anticipating advancements in non-insulin diabetes coverage, supported by clinical evidence and positive regulatory indications.
MedTech Industry Growth and Volume Concerns Addressed Amidst Q4 ReportsA discussion reassures that MedTech volumes were strong in Q4, dismissing concerns of slowdown. The conversation highlights the sector's attractiveness due to ongoing innovation and clinical evidence, projecting sustained growth over the next several years.
Navigating Global Macro Challenges and Advancing Structural Heart InnovationsThe dialogue highlights the company's resilience in managing macroeconomic challenges, particularly in the EPD sector, with a forecasted growth rate in the 8-9% range. It also emphasizes advancements in the structural heart business, including new product launches, label expansions, and acquisitions, aiming to sustain growth and capitalize on emerging markets.
Capital Allocation Strategy: Medtech, Diagnostics, and Nutrition Growth Without MergersThe discussion centered on capital allocation strategies, emphasizing growth in medtech and diagnostics through acquisitions, while asserting that the nutrition business can achieve mid-single-digit growth organically. The speaker highlighted the importance of volume growth, price point adjustments, and strategic investments, particularly in cancer diagnostics, to sustain high growth rates in various business segments.
要点回答
Q：What is Abbott's outlook for growth in 2026?
A：Abbott's outlook for growth in 2026 is powered by innovation, operational excellence, and strategic execution. The company forecasted the midpoint of its 2026 organic sales growth range to be 7% and the midpoint of its adjusted earnings per share range to reflect Ed growth.
Q：What challenges did Abbott's nutrition business face in the fourth quarter?
A：Abbott's nutrition business faced challenges in the fourth quarter, including market share loss in the US pediatric business due to the loss of a large weight contract the previous year and the need to reignite volume growth, which is a challenge faced by many consumer goods businesses today.
Q：What steps is Abbott taking to address the challenges in its nutrition business?
A：To address the challenges in its nutrition business, Abbott began implementing price and promotion initiatives in the fourth quarter to help reignite volume growth. The company is also increasing its focus on innovation, which was deprioritized in the past due to the focus on production and supply chain management.
Q：What are the recent milestones in Abbott's medical device business?
A：Recent milestones in Abbott's medical device business include FDA approval of the Bolt PFA catheter, the CE Mark for the new Tact Deflex dual ablation catheter, and the announcement of double-digit growth in various medical devices such as Navato, Tric Clip, and Mi Clip. The company also completed enrollment in the Catalyst trial evaluating the performance of the left atrial appendage device.
Q：How did Abbott's foundational businesses contribute to its performance?
A：Abbott's foundational businesses, which include rhythm management and vascular, contributed to its performance with double-digit growth in certain areas such as Closure products and growth from Esprit. These investments in foundational businesses are generating very impressive returns and are expected to drive sustainable growth for years to come.
Q：What is the expected favorable impact of foreign exchange on full year reported sales?
A：The expected favorable impact of foreign exchange on full year reported sales is around Ed.
Q：What has caused the change in the company's approach to nutrition and pricing?
A：The challenges faced by CPG businesses, including a significant surge in costs, have resulted in a more price-sensitive consumer base. This has led to a decision to implement price promotion initiatives to invigorate growth and address the decline in volume growth.
Q：What is the strategy for the pipeline and how does it relate to consumer packaged goods?
A：The strategy involves focusing on a pipeline that is either on target or ahead of schedule in certain products and maintaining a strong balance sheet. The company is confident in closing acquisitions and believes the portfolio is well-aligned with consumer packaged goods.
Q：How are the company's challenges in the consumer packaged goods business being addressed?
A：The company has been addressing the challenges by trying to mitigate the impact of higher costs with price increases. However, it has now decided to implement price promotion initiatives and focus on new product development to deal with the decline in volume growth and the increased price sensitivity.
Q：What is the projected timeline for the reinvigoration of growth?
A：The projected timeline for reinvigoration of growth is about a script month process, which is creating a dynamic in the company's growth forecast. This timeline is expected to be shorter than the previous incident in 2022 when supply disruptions occurred.
Q：What impact will 2026 have on the company's revenue growth?
A：The company expects 2026 to have a positive impact on revenue growth with the addition of a new growth vertical through recent acquisitions and the mitigation of core diagnostic headwinds faced in the previous year.
Q：How does the company view the Avid portfolio in EP, especially with new product launches?
A：The company views the Avid portfolio as an important part of its strategy, which includes a range of products that have helped maintain double-digit growth rates even without PFA products. The new products, like Volt, have received positive feedback and are aligned with the company's strategy to provide a toolbox approach for physicians.
Q：What are the company's expectations for business growth in the upcoming year?
A：The company has high expectations for the business, with the belief that it should grow at least in line with the market. The team understands that they should achieve at least high single-digit growth in revenue and profits.
Q：How does the company plan to sustain and possibly accelerate its growth in 2026?
A：The company plans to sustain and possibly accelerate its growth by continuing to support business segments such as cardiovascular and diabetes with new product launches. A large portion of the company is expected to maintain high single-digit growth, with specific product launches and investments contributing to this growth rate.
Q：What challenges did the company face in the previous year related to COVID-19 and how are they factoring this into their forecasts?
A：In the previous year, the company faced significant challenges due to COVID-19, including a decrease in revenue by around $250 million to $500 million and an additional $400 million headwind in P. The forecast for COVID-19's impact in 2026 is around the same number, not expecting any significant growth or decline.
Q：What is the company's perspective on the growth of its diagnostic business and the factors that will influence it?
A：The company expects the diagnostic business to show a nice acceleration in growth as the impact of the BVP (likely a typographical error for 'V') dissipates. Factors influencing this growth include continued momentum in a large portion of the business, lapping effects, and the company's focus on reigniting volume growth.
Q：How does the company view the future of the CGM market and its own position within it?
A：The company believes there is still substantial opportunity for penetration in the CGM market, both from a market perspective and in driving market share and expansion. They estimate that there's a lot of room for growth in all patient groups and geographies, supported by positive data and reimbursement opportunities. They see potential to outperform consensus forecasts, especially in international markets, and are preparing to capitalize on opportunities presented by new products and market share shifts.
Q：What is the potential market share conversion opportunity with the new product launch mentioned?
A：The potential market share conversion opportunity with the new product launch (GS sensor) is significant, offering the possibility of market share conversion and growth. The company is actively working on approval and has been engaging with regulators, payers, and physician groups. With the launch of this differentiated product, there is a strong opportunity for market share gain, particularly among non-insulin users and in international markets.
Q：What are the expectations for margin expansion and strategic alignment in 2026?
A：The company expects to continue expanding margins and to focus on strategically aligned execution, aiming for a yearly improvement of operating margins by about 100 basis points. This is expected to be achieved through gross margin expansion and gaining leverage in the P&L.
Q：What is the current market penetration and future potential for the company's double-digit growth in the pacemaker category?
A：The global low voltage or pacing segment market is around $5 billion, and the company believes it currently represents about 10% of this market, indicating it is in the early innings of growth. The U.S. single chamber segment, which is about 15% of the total market, is around 50% penetrated, suggesting a long opportunity globally, particularly in the U.S.
Q：What has been the approach to capital allocation and M&A decisions?
A：The company's approach to capital allocation is focused on balancing short-term and long-term value creation for shareholders. While growing the dividend, the emphasis is on integrating recent acquisitions like exact sciences and pursuing smaller tuck-in deals. No specific timing was provided for divestitures or spin-offs.
Q：Can you discuss the confidence in pricing strategy and profitability profile for the nutrition segment?
A：The company's confidence in its pricing strategy is based on testing and results, which have shown encouraging signs. The approach varies by market and profitability is managed by adjusting marketing and promotional activities. The goal is to maintain a steady profile, and the company believes it has appropriately priced its products.
Q：What are the market outlooks for diagnostics in China and the rest of the world?
A：In China, the company is experiencing headwinds related to VBP and faces challenges in smaller program categories. Despite this, the company has a new management team in place and is focusing on core lab oncology testing where it has low market share. Excluding China, diagnostics are expected to grow at a mid-single-digit rate this year, up from 2025 levels, driven by more stable growth in China and acceleration in other parts of the portfolio.
Q：What are the expectations for non-insulin type II diabetes coverage and how might it play out in the first half of the year?
A：There is optimism for non-insulin type II diabetes coverage expansion, supported by clinical data from studies showing improved A1C and better time and range. CMS is supportive, and the team is preparing for potential language changes in the first half. However, the exact timeline is uncertain due to the usual 90-day comment period and 60-day review process following language changes.
Q：What evidence supports the expansion of coverage for the mentioned technology?
A：The expansion of coverage is supported by the American Diabetes Association (ADA), other physician groups, and backed by clinical evidence from three studies with the patient segment demonstrating improved A1C and time in range.
Q：What might the potential new coverage for the technology entail?
A：The potential new coverage could be announced in the first half and is expected to be a significant opportunity for the market. The nature of the coverage is anticipated to be detailed in future CMS language, which will be subject to a comment and review period.
Q：How important are the preparation and setup of the company in the context of potential new coverage?
A：Preparation and setup are critical as they will determine how well the company can capitalize on the new coverage. The readiness of the sales force and integration with health systems will play an important role in the company's success if and when the new coverage is implemented.
Q：What is the outlook for Medtech market growth, especially in Q4 and into 2026?
A：The outlook for Medtech market growth suggests a more aligned performance in Q1 and an improvement in the second half of the year. Q3 will show some acceleration, although not to the extent of a one-year comparison. The Medtech volumes are not expected to slow down, driven by innovation and clinical evidence, suggesting a very attractive segment for the future.
Q：Are there concerns about Medtech volumes in Q4 and how does the company view the future of this segment?
A：There is no indication that Medtech volumes in Q4 were short; in fact, they were reported to be good across all categories. The evidence and guidance do not suggest that Medtech volumes are slowing down. The segment is viewed as very attractive due to innovation and the potential for growth over many years.
Q：What potential challenges might arise from a macro perspective and what is the company's approach to these challenges?
A：The company acknowledges concerns about geopolitics but believes that the team's resilience and experience in navigating challenging circumstances will allow them to continue driving the business forward. They are mindful of the challenges and will rely on their team's ability to adapt and succeed despite potential macroeconomic difficulties.
Q：What product developments and business strategies are driving growth in the structural heart business?
A：The structural heart business growth is driven by multiple product developments and strategies, including a diverse range of new products and upcoming label expansions. There are also opportunities in various markets, such as the U.S., and international markets like Japan. Additionally, acquisitions like Laura Lab, an AI-powered imaging interventional cardiology company, are enhancing the company's product offerings and aiding in pre-procedural imaging. The business is investing in its pipeline and clinical teams to ensure sustainable future growth.
Q：Is inorganic growth still a focus for the company or is there potential for the business to return to mid single-digit growth without external business development initiatives?
A：Inorganic growth through acquisitions is still a focus area for the company, as evidenced by their strategies for Medtech and diagnostics franchises. However, the company is also confident that its focus on volume growth in the nutrition business and internal product developments can achieve mid single-digit growth without the need for external business development initiatives.
Abbott Laboratories
Follow
